Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 4/2021

LEVOFLOXACIN VERSUS CEFIXIME AS AN EMPIRIC TREATMENT IN ACUTE BACTERIAL PROSTATITIS

CĂTĂLIN PRICOP 1,2#, DRAGOȘ PUIA 1,2, DANIEL ANDONE 2, SILVIU LAȚCU 3, GEORGE DANIEL RĂDĂVOI 5*, IOAN CORDOȘ 5#, VIOREL JINGA 5, TUDOR PROCA 5, ALIN CUMPĂNAȘ 3

1“Grigore T. Popa” University of Medicine and Pharmacy, Faculty of Medicine, Discipline of Urology, 16 Universităţii Street, 700115, Iaşi, Romania
2 “Dr. C.I. Parhon” Clinical Hospital, Clinic of Urology, 50 Carol I Boulevard, 700503, Iaşi, Romania
3 “Victor Babeș” University of Medicine and Pharmacy, Faculty of Medicine, Discipline of Urology, Timișoara, Romania
4 “Grigore T. Popa” University of Medicine and Pharmacy, Faculty of Medicine, Department of Mother and Child Medicine, 16 Universităţii Street, Iaşi, Romania
5 “Carol Davila” University of Medicine and Pharmacy, Faculty of Medicine, Discipline of Urology, 37 Dionisie Lupu Street, Bucharest, Romania

Download Full Article PDF

Acute bacterial prostatitis (ABP) is a clinical condition frequently encountered in clinical practice, but there is a lack of consensus for the diagnosis, investigations, and treatment for this pathology. We have enrolled patients diagnosed with acute prostatitis in three academic urological centres between 2019 - 2020 and followed-up prospectively their evolution under two different frequently used antibiotics-fluoroquinolones and cephalosporins, both combined or not with alpha-blockers. All patients received standard start-up treatment. A total of 154 patients were included. Both groups had similar side effects rates ranging from 8.97% to 11.84%. Both groups had similar positive urine culture 15.38% for group A, respectively 14.47% for group B. Although it is an ongoing study, we can confirm that fluoroquinolones and cephalosporins, with or without alpha-blocker, are as effective and tolerated in enhancing empirical treatment initiated at admission for patients with acute bacterial prostatitis.